SHOCK: Biotech Stock SURGES 27%, But Director DUMPS 18% Now! Is CYTK DOOMED?
Why would a company director dump nearly 18% of their stock after it surged 27% in a year? B. Lynne Parshall, a Cytokinetics director, sold 5,000 shares worth over $320,000, signaling potential concerns for this biopharmaceutical giant. Despite celebrating a significant drug approval in China with a $7.5 million payment from Sanofi, the company is facing intense volatility. It's grappling with a critical December 26th FDA decision for its drug aficamten, while simultaneously fending off a class-action lawsuit alleging misleading statements about approval timelines. With such dramatic twists and turns, understanding whether to hold or sell is crucial, so subscribe now to our channel for essential market analysis.
Tags/Hashtags: #cytokinetics #biotech #cytokinetics #sanofi
Leave a Reply